And meanwhile, the predicted drugs, such as TESTOSTERONE targeting CXCL10 and CYCLOSPORINE targeting IL15, may potentially enhance immune function and alleviate symptoms and immune-mediated inflammation-related damage in patients with pSS. The gene discussed is CXCL10; the disease is peeling skin syndrome.